|

Melphalan Clinical Trials

39 actively recruiting trials across 19 locations

Also known as: 148-82-3, 4-[bis(2-chloroethyl)amino]-L-phenylalanine, Alanine Nitrogen Mustard, Alkeran, Alkeran® +24 more

Pipeline

Phase 1: 11Phase 2: 17Phase 3: 5Phase 1/2: 4

Top Sponsors

City of Hope Medical Center4
National Cancer Institute (NCI)3
Masonic Cancer Center, University of Minnesota3
M.D. Anderson Cancer Center3
Washington University School of Medicine2

Indications

Cancer37
Multiple Myeloma9
Acute Myeloid Leukemia8
Myelodysplastic Syndrome7
Acute Lymphoblastic Leukemia7

Other7 trials

Allogeneic Hematopoietic Cell Transplantation From HLA-matched Donor After Flu-Mel-PTCy Versus Flu-Mel-ATG Reduced-intensity Conditioning

Phase 2

Clinical Trial Investigating the Chemotherapeutic Compound Treosulfan (Trecondi® Ideogen) in Myeloma Patients

Phase 2

Conditioning Regimen of Melphalan-busulfan and Fludarabine: a Randomized Study of Different Dose of Melphalan

Phase 3

High Risk Neuroblastoma Study 1.8 of SIOP-Europe (SIOPEN)

Phase 3

Intrathecal Chemotherapy for Central Nervous System Metastasis in Retinoblastoma

N/A

Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple Myeloma

Phase 2

Topotecan and Melphalan for Retinoblastoma

Phase 3

Duarte, California5 trials

225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome

City of Hope Medical Center

Phase 1

Orca-T Following Chemotherapy and Total Marrow and Lymphoid Irradiation for the Treatment of Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia or Myelodysplastic Syndrome

City of Hope Medical Center

Phase 1

The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation

City of Hope

Phase 1/2

Total Marrow and Lymphoid Irradiation, Fludarabine, and Melphalan Before Donor Stem Cell Transplant in Treating Participants With High-Risk Acute Leukemia or Myelodysplastic Syndrome

City of Hope Medical Center

Phase 1

Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation After Reduced Intensity Conditioning

City of Hope Medical Center

Phase 2

Birmingham, Alabama3 trials

A Study to Give Treatment Inside the Eye to Treat Retinoblastoma

Children's Hospital of Alabama

Phase 2

Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma

Children's Hospital of Alabama

Phase 3

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

University of Alabama at Birmingham Cancer Center

Phase 2

Minneapolis, Minnesota3 trials

Auto Stem Cell Transplant for Lymphoma Patients

Masonic Cancer Center, University of Minnesota

Phase 2

MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies

University of Minnesota Masonic Cancer Center

Phase 2

Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma

Masonic Cancer Center, University of Minnesota

Phase 2

Houston, Texas3 trials

Bendamustine With or Without Cyclophosphamide in Preventing GVHD in Patients Undergoing Stem Cell Transplant

M D Anderson Cancer Center

Phase 1/2

Personalized NK Cell Therapy in CBT

M D Anderson Cancer Center

Phase 2

Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma

MD Anderson Cancer Center

Phase 2

Boston, Massachusetts2 trials

IS-free Treg HaploHCT

Dana Farber Cancer Institute

Phase 1

SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells

Massachusetts General Hospital

Phase 1

St Louis, Missouri2 trials

Impact of Recombinant Human Interleukin-7 (CYT107) on Tumor Clearance and Immune Reconstitution in Multiple Myeloma Patients After Autologous Hematopoietic Cell Transplant

Washington University School of Medicine

Phase 1

Pilot Study of Memory-like Natural Killer (ML NK) Cells After TCRαβ T Cell Depleted Haploidentical Transplant in AML

Washington University School of Medicine

Phase 1/2

Memphis, Tennessee2 trials

CD45RA-depleted CD19-CAR T Cell Consolidation After TCRαβ+/CD19 B Cell-depleted Haploidentical Hematopoietic Cell Transplantation for Relapsed/Refractory CD19+ ALL and Lymphoma

St. Jude Children's Research Hospital

Phase 1

TCRαβ-depleted Progenitor Cell Graft With Early Memory T-cell DLI, Plus Selected Use of Blinatumomab, in naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies

St. Jude Children's Research Hospital

Phase 1

Orange, California1 trial

Risk-ADAPTed Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation

Chao Family Comprehensive Cancer Center, University of California Irvine

Phase 2

Palo Alto, California1 trial

Early Trial of Allogeneic Hematopoietic Stem Cell Transplantation for Patients Who Will Receive a Kidney Transplant From the Same Donor

Lucile Packard Children's Hospital

Phase 1/2

Stanford, California1 trial

Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft

Stanford University

Phase 1

Derby, Connecticut1 trial

Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis

Smilow Cancer Hospital-Derby Care Center

Phase 3

Atlanta, Georgia1 trial

Personalized Autologous Transplant for Multiple Myeloma

Winship Cancer Institute of Emory University

Phase 1

Chicago, Illinois1 trial

Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients With Relapsed Hematologic Cancers Undergoing a Second Donor Stem Cell Transplant

University of Chicago Comprehensive Cancer Center

Phase 1

Baltimore, Maryland1 trial

Reduced Intensity Haploidentical BMT for High Risk Solid Tumors

The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2

Basking Ridge, New Jersey1 trial

A Study of Melphalan With or Without Siltuximab in People With Multiple Myeloma Having an Autologous Stem Cell Transplant

Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)

Phase 2

Rochester, New York1 trial

Umbilical Cord Blood Transplantation From Unrelated Donors

Wilmot Cancer Institute

Philadephia, Pennsylvania1 trial

Two Step Haplo With Radiation Conditioning

Sidney Kimmel Cancer Center at Thomas Jefferson University

Phase 2

Pittsburgh, Pennsylvania1 trial

Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT

UPMC Children's Hospital of Pittsburgh

Phase 2

Seattle, Washington1 trial

Ruxolitinib Before, During and After Hematopoietic Cell Transplant in Older Patients With Myelofibrosis and Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes

Fred Hutch/University of Washington Cancer Consortium

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.